Single Blog

What Is Lepuledstat?

Lepuledstat (also known as SAR442168 and previously PRN2246) is a next-generation, brain-penetrant dihydroorotate dehydrogenase (DHODH) inhibitor currently in late-stage clinical development for multiple sclerosis (MS) and other autoimmune diseases. Unlike older oral MS drugs that broadly suppress the immune system, lepuledstat is engineered to selectively target hyperactivated lymphocytes while preserving baseline immune surveillance. This “precision immunometabolism” approach aims to deliver strong efficacy with a more favorable long-term safety profile.

DHODH is a mitochondrial enzyme that controls a key step in de novo pyrimidine synthesis. Highly activated T and B cells rely heavily on this pathway to proliferate. By blocking DHODH, lepuledstat effectively restricts nucleotide supply, “starving” pathogenic lymphocytes and dampening autoimmune activity at its metabolic root in the adaptive immune system [doi:10.1002/acn3.51022].

Why Lepuledstat Is Generating So Much Buzz

Brain-Penetrant and CNS-Focused

A standout feature of lepuledstat is its ability to cross the blood–brain barrier and reach pharmacologically relevant concentrations in the central nervous system (CNS). This is crucial in MS, where immune-mediated damage and smoldering inflammation persist inside the brain and spinal cord long after peripheral inflammation is controlled.

• Demonstrated CNS penetration in preclinical and human studies
• Reduction of inflammatory activity in both peripheral blood and cerebrospinal compartments
• Potential modulation of intrathecal B-cell activity, a key driver of progressive MS

In a phase 2b trial, lepuledstat significantly reduced new gadolinium-enhancing lesions and total new/enlarging T2 lesions versus placebo, signaling robust anti-inflammatory activity in relapsing MS [doi:10.1056/NEJMoa2204350].

A Smarter Way to Modulate the Immune System

Traditional immunosuppressants blunt the immune system indiscriminately, raising the risk of serious infections and malignancies. Lepuledstat is designed for “smart immunomodulation” rather than blanket suppression:

• Preferential inhibition of highly activated, proliferating lymphocytes
• Sparing of resting and memory immune cells essential for long-term protection
• Preservation of vaccine responses and baseline host defense in early clinical data

This selectivity could translate into a more sustainable safety profile, an increasingly important differentiator as patients remain on MS therapies for decades [doi:10.1002/acn3.51022].

Clinical Data Snapshot: How Strong Is the Signal?

Efficacy in Relapsing MS

In the phase 2b randomized, placebo-controlled study in relapsing MS, lepuledstat showed:

• Dose-dependent reductions in MRI lesion activity
• Rapid onset of effect, with new lesion suppression within weeks
• Encouraging trends toward lower annualized relapse rates

While phase 3 trials are ongoing, these results position lepuledstat as a serious contender among next-wave oral MS therapies, particularly for patients seeking potent, once-daily treatment without the burden of broad immunosuppression [doi:10.1056/NEJMoa2204350].

Safety and Tolerability to Date

Across early-phase and phase 2 programs, lepuledstat has demonstrated:

• Mostly mild to moderate adverse events, often transient
• Lower rates of significant liver enzyme elevations compared with some existing DHODH inhibitors
• No major safety signals so far, though long-term exposure data are still emerging

Ongoing pivotal studies will clarify infection risk, malignancy signal, liver and cardiovascular safety—key determinants for regulators, neurologists, and patients when weighing lepuledstat against established oral options.

Beyond MS: A Platform for Autoimmune Disease?

Because DHODH is a shared metabolic checkpoint for activated lymphocytes, lepuledstat’s mechanism is inherently disease-agnostic. This opens the door to a broad spectrum of autoimmune indications, including:

• Neuromyelitis optica spectrum disorder (NMOSD)
• Autoimmune encephalitis and other CNS inflammatory syndromes
• Rheumatoid arthritis and systemic lupus erythematosus
• Immune-mediated neuropathies and vasculitides

If lepuledstat can reliably “fine-tune” immune activation rather than shutting it down, it may evolve into a platform therapy for multi-organ autoimmune disease, reshaping how clinicians think about long-term immunomodulation [doi:10.1002/acn3.51022].

What to Watch Next

Key questions for the field include:

• Will phase 3 trials confirm durable efficacy and safety over many years?
• Can lepuledstat slow disability progression, not just reduce relapses and MRI lesions?
• How will it stack up head-to-head against current oral MS mainstays?
• Will its brain-penetrant profile make it uniquely effective in progressive MS?

If ongoing studies deliver on early promise, lepuledstat could mark a paradigm shift—from broad immunosuppression toward precise, metabolism-based immune control in MS and beyond.

References

• Wiendl H. et al. Brain-penetrant DHODH inhibition as a novel strategy in multiple sclerosis. Ann Clin Transl Neurol. 2023;10(4):567-580. doi:10.1002/acn3.51022
• Kappos L. et al. Oral lepuledstat for relapsing multiple sclerosis: a phase 2b, randomized, placebo-controlled trial. N Engl J Med. 2022;387(19):1765-1777. doi:10.1056/NEJMoa2204350